1,458 results on '"Zielinski C"'
Search Results
2. Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
3. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL
4. Time to treat the climate and nature crisis as one indivisible global health emergency
5. ESMO Open: from Cancer Horizons to Science for Optimal Cancer Care—a tale stretching over 8 years
6. Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients
7. Brain metastases as first manifestation of advanced cancer: exploratory analysis of 459 patients at a tertiary care center
8. ESMO-Magnitude of Clinical Benefit Scale version 1.1
9. Time to treat the climate and nature crisis as one indivisible global health emergency.
10. COP27 climate change conference: Urgent action needed for Africa and the world
11. COP27 Climate Change Conference: urgent action needed for Africa and the world
12. Longitudinal analysis of hemostasis biomarkers in cancer patients during antitumor treatment
13. ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
14. Un corpus multimodal pour étudier les interactions par visioconférence pour le développement des compétences techno-pédagogiques en didactique des langues et formation de formateurs
15. Time to treat the climate and nature crisis as one indivisible global health emergency.
16. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
17. Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortality
18. Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients – results from the Vienna Cancer And Thrombosis Study (CATS)
19. Measuring sequences of keystrokes with jsPsych: Reliability of response times and interkeystroke intervals
20. Editorial : Climate change conference, COP27: Urgent action needed for Africa and the world
21. Reply to the letter to the editor ‘Toxicity adjustment in the ESMO-MCBS: a Gestalt approach?’ by Del Paggio
22. Onkologie
23. Ventiltriebtechnologien für die Herausforderung Motorrad – Besonderheiten im Vergleich zu Automobilmotoren
24. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
25. Decreased body mass index is associated with impaired survival in lung cancer patients with brain metastases: A retrospective analysis of 624 patients
26. Presence of varicose veins in cancer patients increases the risk for occurrence of venous thromboembolism
27. Prognostic impact of breast cancer subtypes in elderly patients
28. Introducing pro and con discussions in ESMO Open—Cancer Horizons
29. Onkologie
30. Mammakarzinom
31. Application of the RNT Robot to Milling and Polishing
32. Abscopal-Effekt in der Therapie des malignen Melanoms
33. Microparticle‐associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients
34. ESMO Clinical Practice Guidelines: adapting and adopting new approaches for development, implementation and audit
35. HER-2/neu in Breast Cancer: A Possible Means of Therapy?
36. Object-Oriented Approach to Programming a Robot System
37. Thrombosis risk and survival in cancer patients with elevated C‐reactive protein
38. Sensor-Based Reactive Robot Control
39. Humoral and cellular immune responses and their kinetics vary in dependence of diagnosis and treatment in immunocompromised patients upon COVID-19 mRNA vaccination
40. Reply to the letter to the editor ‘The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice’ by Hartmann and the letter ‘Comment on ESMO Magnitude of Clinical Benefit Scale’ by Muhonen et al.
41. Zelluläre Immunitätsparameter bei opiatabhängigen Patienten
42. Therapie des metastasierenden Mammakarzinoms
43. Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed?
44. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)
45. 229MO Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormone-receptor+/HER2- metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study
46. 415P Comparison of cetuximab every 2 weeks versus standard once-weekly administration for the first-line treatment of RAS wild-type metastatic colorectal cancer among patients with left- and right-sided primary tumor location
47. P-52 Overall survival with cetuximab every 2 weeks vs standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumor location
48. 472P Prevention of metastasis formation by combination therapy targeting Her2 and PD-L1 in Her2-expressing tumors based on observed efficacious vaccination against Her2-positive tumors
49. 1536P HERIZON: A phase II study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine plus standard of care chemotherapy in patients with HER2+ advanced stomach cancer - Dose-dependent anti-cancer antibodies correlating with improved clinical outcome
50. Erratum to: Measuring sequences of keystrokes with jsPsych: Reliability of response times and interkeystroke intervals
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.